WuXi’s New Unit Joins Race For Drug Innovation In China
This article was originally published in The Pink Sheet Daily
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.
You may also be interested in...
Authorities in China appear to be taking a tough early stance in the enforcement of a new national Biosecurity Law that took effect in mid-April, with an imported human cell shipment in Shanghai being seized.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.